Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer

Hong Lin He; Ying En Lee; Hsin Pao Chen; Chung Hsi Hsing; I. Wei Chang; Yow Ling Shiue; Sung Wei Lee; Chao Tien Hsu; Li Ching Lin; Ting Feng Wu; Chien Feng Li

doi:10.1016/j.yexmp.2015.03.029

Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer

Hong Lin He, Ying En Lee, Hsin Pao Chen, Chung Hsi Hsing, I. Wei Chang, Yow Ling Shiue, Sung Wei Lee, Chao Tien Hsu, Li Ching Lin, Ting Feng Wu, Chien Feng Li

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Genes associated with protein folding have been found to have certain prognostic significance in a subset of cancers. The aim of this study is to evaluate the clinical impact of DNAJC12 expression in patients with rectal cancers receiving neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery. Through data mining from a public transcriptomic dataset of rectal cancer focusing on genes associated with protein folding, we found that DNAJC12, a member of the HSP40/DNAJ family, was the most significant such gene correlated with the CCRT response. We further evaluated the expression of DNAJC12 by immunohistochemistry in the pre-treatment tumor specimens from 172 patients with rectal cancers. From this set, we statistically analyzed the association of DNAJC12 expression with various clinicopathological factors, tumor regression grade, overall survival (OS), disease-free survival (DFS) and local recurrence-free survival (LRFS). High expression of DNAJC12 was significantly associated with advanced pre- and post-treatment tumor status (. P

Original language	English
Pages (from-to)	338-345
Number of pages	8
Journal	Experimental and Molecular Pathology
Volume	98
Issue number	3
DOIs	https://doi.org/10.1016/j.yexmp.2015.03.029
Publication status	Published - Jun 1 2015
Externally published	Yes

Keywords

CCRT
Chemoradiotherapy
DNAJC12
HSP40
Rectal cancer

ASJC Scopus subject areas

Molecular Biology
Clinical Biochemistry
Pathology and Forensic Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.yexmp.2015.03.029

Cite this

@article{56509549b58d4d95bcf38d8816d718ef,

title = "Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer",

abstract = "Genes associated with protein folding have been found to have certain prognostic significance in a subset of cancers. The aim of this study is to evaluate the clinical impact of DNAJC12 expression in patients with rectal cancers receiving neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery. Through data mining from a public transcriptomic dataset of rectal cancer focusing on genes associated with protein folding, we found that DNAJC12, a member of the HSP40/DNAJ family, was the most significant such gene correlated with the CCRT response. We further evaluated the expression of DNAJC12 by immunohistochemistry in the pre-treatment tumor specimens from 172 patients with rectal cancers. From this set, we statistically analyzed the association of DNAJC12 expression with various clinicopathological factors, tumor regression grade, overall survival (OS), disease-free survival (DFS) and local recurrence-free survival (LRFS). High expression of DNAJC12 was significantly associated with advanced pre- and post-treatment tumor status (. P",

keywords = "CCRT, Chemoradiotherapy, DNAJC12, HSP40, Rectal cancer",

author = "He, {Hong Lin} and Lee, {Ying En} and Chen, {Hsin Pao} and Hsing, {Chung Hsi} and Chang, {I. Wei} and Shiue, {Yow Ling} and Lee, {Sung Wei} and Hsu, {Chao Tien} and Lin, {Li Ching} and Wu, {Ting Feng} and Li, {Chien Feng}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/j.yexmp.2015.03.029",

language = "English",

volume = "98",

pages = "338--345",

journal = "Experimental and Molecular Pathology",

issn = "0014-4800",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer

AU - He, Hong Lin

AU - Lee, Ying En

AU - Chen, Hsin Pao

AU - Hsing, Chung Hsi

AU - Chang, I. Wei

AU - Shiue, Yow Ling

AU - Lee, Sung Wei

AU - Hsu, Chao Tien

AU - Lin, Li Ching

AU - Wu, Ting Feng

AU - Li, Chien Feng

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Genes associated with protein folding have been found to have certain prognostic significance in a subset of cancers. The aim of this study is to evaluate the clinical impact of DNAJC12 expression in patients with rectal cancers receiving neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery. Through data mining from a public transcriptomic dataset of rectal cancer focusing on genes associated with protein folding, we found that DNAJC12, a member of the HSP40/DNAJ family, was the most significant such gene correlated with the CCRT response. We further evaluated the expression of DNAJC12 by immunohistochemistry in the pre-treatment tumor specimens from 172 patients with rectal cancers. From this set, we statistically analyzed the association of DNAJC12 expression with various clinicopathological factors, tumor regression grade, overall survival (OS), disease-free survival (DFS) and local recurrence-free survival (LRFS). High expression of DNAJC12 was significantly associated with advanced pre- and post-treatment tumor status (. P

AB - Genes associated with protein folding have been found to have certain prognostic significance in a subset of cancers. The aim of this study is to evaluate the clinical impact of DNAJC12 expression in patients with rectal cancers receiving neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery. Through data mining from a public transcriptomic dataset of rectal cancer focusing on genes associated with protein folding, we found that DNAJC12, a member of the HSP40/DNAJ family, was the most significant such gene correlated with the CCRT response. We further evaluated the expression of DNAJC12 by immunohistochemistry in the pre-treatment tumor specimens from 172 patients with rectal cancers. From this set, we statistically analyzed the association of DNAJC12 expression with various clinicopathological factors, tumor regression grade, overall survival (OS), disease-free survival (DFS) and local recurrence-free survival (LRFS). High expression of DNAJC12 was significantly associated with advanced pre- and post-treatment tumor status (. P

KW - CCRT

KW - Chemoradiotherapy

KW - DNAJC12

KW - HSP40

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=84926306574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926306574&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2015.03.029

DO - 10.1016/j.yexmp.2015.03.029

M3 - Article

C2 - 25805104

AN - SCOPUS:84926306574

SN - 0014-4800

VL - 98

SP - 338

EP - 345

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

IS - 3

ER -

Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this